ArticleOncoTargets and therapy2020
Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.Nature communications · 2025Article
- Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review.Oncology letters · 2025Article
- Perioperative serplulimab‑based chemoimmunotherapy in stage IV large cell neuroendocrine carcinoma of the lung: A case report.Oncology letters · 2024Article
- Bronchoscopic Interventional Therapy Combined With Pembrolizumab in the Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report.The clinical respiratory journal · 2024Article
- Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma.Journal of thoracic disease · 2023Article
- Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis.Cancer medicine · 2023Article
- A multiple detection method for distinguishing gene mutations based on melting curves of extended quenching probes.Heliyon · 2022Article
- Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab.Cancer reports (Hoboken, N.J.) · 2022Article
- Endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime for advanced pulmonary large-cell neuroendocrine carcinoma as a first-line treatment: A case report.Open life sciences · 2022Article
- Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.Journal for immunotherapy of cancer · 2021Article
- Large Cell Neuroendocrine Carcinoma in the Sinonasal Cavity with Large Intracranial Extension Treated with Endonasal Endoscopic and Transcranial Combined Surgery: A Case Report.NMC case report journal · 2021Article
- Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.Frontiers in oncology · 2021Review
- Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-cell neuroendocrine lung carcinoma (LCNELC) is classified into lung neuroendocrine tumors according to WHO 2015 classification guidelines and represents approximately 3% of all lung cancer. Because of the rarity of LCNELC, there is a lack of prospective studies guiding treatment. Here, we report a case of a patient with pT2aN2M0 stage IIIA LCNELC (drug-sensitive EGFR/ALK mutation-negative, PD-L1-negative but tumor mutation burden (TMB) high), who progressed rapidly after surgery but achieved a complete response to subsequent immune checkpoint inhibitor (ICI) therapy. The concentration of circulating tumor DNA (ctDNA) following the treatment course strongly reflects the response to ICI therapy. This report highlights the efficacy of ICI treatment in metastatic LCNELC patients with a high TMB and suggests that ctDNA analysis in detecting molecular residual disease may facilitate the personalization of ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.